XML 16 R4.htm IDEA: XBRL DOCUMENT v3.23.4
Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Income Statement [Abstract]        
Revenues $ 2,058,028 $ 2,055,803 $ 5,919,786 $ 7,993,805
Cost of sales 353,450 683,375 1,072,934 3,991,234
Gross profit 1,704,578 1,372,428 4,846,852 4,002,571
Operating expenses:        
Wage and salary expense 698,030 849,371 2,077,362 2,949,386
Professional fees 418,294 82,710 782,286 256,807
Accounting and legal expense 408,957 191,007 782,495 567,086
Technology expense 410,612 238,577 1,010,374 690,875
General and administrative expense 613,834 229,526 1,264,902 1,392,130
Total operating expenses 2,549,727 1,591,191 5,917,419 5,856,284
Operating loss (845,149) (218,763) (1,070,567) (1,853,713)
Nonoperating income (expense)        
Change in fair value of warrant liability 925,320 (443,308)
Interest income 8,396 4,198 8,396
Gain (loss) on disposal of assets 2,200
Interest expense (251,778) (130,107) (494,904) (140,626)
Total nonoperating income (expense) 673,542 (121,711) (934,014) (130,030)
Net loss from continuing operations (171,607) (340,474) (2,004,581) (1,983,743)
Net loss on discontinued operations (3,353,507) (188,268) (4,123,028) (623,096)
Net loss (3,525,114) (528,742) (6,127,609) (2,606,839)
Net loss attributable to TRxADE Health, Inc. (3,525,114) (503,003) (6,127,609) (2,546,913)
Net loss attributable to non-controlling interests $ (25,739) $ (59,926)
Net loss per common share from continuing operations        
Basic $ (0.22) $ (0.57) $ (2.83) $ (3.52)
Diluted (0.07) (0.57) (0.87) (3.51)
Net loss per common share from discontinued operations        
Basic (4.35) (0.34) (5.82) (1.14)
Diluted (1.42) (0.34) (1.79) (1.14)
Net loss attributable to common stockholders        
Basic (4.57) (0.91) (8.65) (4.66)
Diluted $ (1.49) $ (0.91) $ (2.66) $ (4.64)
Weighted average common shares outstanding        
Basic 771,192 549,977 708,116 546,879
Diluted 2,363,233 551,724 2,300,157 548,626